Shiying Dong

Dr. Shiying Dong


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in Journal of Neurotrauma
Verified
Journal Article
Closed access
SDShiying Dong
Shiying Dong
HZHongwei Zhao
Hongwei Zhao
MNMeng Nie
Meng Nie
ZSZhuang Sha
Zhuang Sha
JFJiancheng Feng
Jiancheng Feng
Rongcai JiangRongcai Jiang
Rongcai Jiang
Traumatic brain injury (TBI) persists as a substantial clinical dilemma, largely because of the absence of effective treatments. This challenge is exacerbated by the hindered clearance of intracranial metabolic byproducts and the continual accrual of deleterious proteins. The glymphatic system (GS) and meningeal lymphatic vessels (MLVs), key elements of the intracranial lymphatic network, play critical roles in the clearance of harmful substances. Cannabidiol (CBD) has shown promise in reducing metabolite overload and bolstering cognitive performance in various neurodegenerative diseases. The precise mechanisms attributing to its beneficial effects in TBI scenarios, however, are yet to be distinctly understood. Utilizing a fluid percussion injury paradigm, our research adopted a multifaceted approach, encompassing behavioral testing, immunofluorescence and immunohistochemical analyses, laser speckle imaging, western blot techniques, and bilateral cervical efferent lymphatic ligation. This methodology aimed to discern the influence of CBD on both neurological outcomes and intracranial lymphatic clearance in a murine TBI model. We observed that CBD administration notably ameliorated motor, memory, and cognitive functions, concurrently with a significant reduction in the concentration of phosphorylated tau protein and amyloid-β. In addition, CBD expedited the turnover and elimination of intracranial tracers, increased cerebral blood flow, and enhanced the efficacy of fluorescent tracer migration from MLVs to deep cervical lymph nodes (dCLNs). Remarkably, CBD treatment also induced a reversion in aquaporin-4 (AQP-4) polarization and curtailed neuroinflammatory indices. A pivotal discovery was that the surgical interruption of efferent lymphatic conduits in the neck nullified CBD's positive contributions to intracranial waste disposal and cognitive improvement, yet the anti-neuroinflammatory actions remained unaffected. These insights suggest that CBD may enhance intracranial metabolite clearance, potentially via the regulation of the intracranial lymphatic system, thereby offering neurofunctional prognostic improvement in TBI models. Our findings underscore the potential therapeutic applicability of CBD in TBI interventions, necessitating further comprehensive investigations and clinical validations to substantiate these initial conclusions.

27 February 2024 in Journal of Neurotrauma
Verified
Journal Article
Closed access
YQYu Qian
Yu Qian
SDShiying Dong
Shiying Dong
MNMeng Nie
Meng Nie
YTYu Tian
Yu Tian
MLMingqi Liu
Mingqi Liu
Rongcai JiangRongcai Jiang
Rongcai Jiang
Cardiac injury is a common complication following traumatic brain injury (TBI) that can lead to poor clinical outcomes. Angiotensin II type 2 receptor (AT2R) activation exerts protective roles in the brain and heart, yet its potential impact on TBI or TBI-induced cardiac deficits remains elusive. The goal of this study was to investigate the influence of AT2R activation on recovery after TBI-induced cognitive and cardiac injury using the selective nonpeptide AT2R agonist compound 21 (C21). TBI was induced by cortical impact injury in male adult C57BL/6J mice, and the mice received C21 (0.03 mg/kg, intraperitoneally) starting from 24 h after TBI and continuing once daily. C21 facilitated cognitive function recovery until 1 month after TBI. C21 alleviated blood-brain barrier leakage and brain edema and inhibited the expression of proinflammatory cytokines in the brain after 3 consecutive days of treatment. C21 improved cerebral blood flow after 1 month, although the lesion volume was not affected. C21 also reduced the expression of proinflammatory cytokines in the heart after a 3-day consecutive treatment. Meanwhile, C21 benefited cardiac function, as identified by increased left ventricular ejection fraction 1 month after TBI. In addition, C21 alleviated TBI-induced cardiac hypertrophy and fibrosis; however, blood pressure was not affected. Our results demonstrate that AT2R activation ameliorates TBI-induced neurological and cardiac deficits.

24 July 2026 in Medicine
Verified
Journal Article
Open access
FLFangbing Li
Fangbing Li
SDShiying Dong
Shiying Dong
FSFei Song
Fei Song
DWDi Wu
Di Wu
DADejian An
Dejian An
CPChongjie Pang
Chongjie Pang
Using Global Burden of Disease 2021 estimates, we characterized long-term trends (1990–2021), age-specific patterns, and socioeconomic/geographic disparities in the global meningitis burden, and descriptively benchmarked country-level burden relative to development level using frontier analysis. We analyzed incidence, mortality, prevalence, and disability-adjusted life years using age-standardized rates across locations and time. We further assessed temporal trends, age-specific patterns, socioeconomic and geographic inequalities, decomposition of burden changes, and development-conditioned frontier benchmarks, and generated projections to 2050 using Bayesian age-period-cohort forecasting models. From 1990 to 2021, the global meningitis burden among children under 5 years declined across major indicators. Projections suggested continued overall reductions to 2050 under the continuation of observed historical patterns. Despite this progress, the burden remained unevenly distributed. Neonates had the highest burden across major metrics, and low-SDI settings continued to experience substantially higher incidence, mortality, and disability-adjusted life year rates than high-SDI settings. Inequality analyses further indicated that relative disparities persisted over time. The global burden of meningitis among children under 5 years has declined and is projected to continue decreasing. However, the remaining burden is concentrated among neonates and in lower-SDI settings. Because these patterns were identified consistently across age-specific, SDI-stratified, and inequality analyses, sustained progress will require continued burden reduction together with equity-oriented prevention, diagnostic access, and newborn-care strategies targeted to neonates and lower-SDI high-burden settings.